TP53 and nonpapillary renal cell carcinoma: The application of emerging biomarkers (e.g., TMB, TP53, ICB, and microsatellite state) are also significantly correlated with the targeted treatment of ccRCC (Au et al., 2021; Krishna et al., 2021).